Symlin is a drug owned by Astrazeneca Ab. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 16, 2019. Details of Symlin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5686411 | Amylin agonist peptides and uses therefor |
Mar, 2019
(5 years ago) |
Expired
|
| US6114304 | Methods for regulating gastrointestinal motility |
Sep, 2017
(7 years ago) |
Expired
|
| US5814600 | Method and composition for treatment of insulin requiring mammals |
Sep, 2015
(9 years ago) |
Expired
|
| US6608029 | Methods for regulating gastrointestinal motility |
Sep, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Symlin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Symlin's family patents as well as insights into ongoing legal events on those patents.
Symlin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Symlin's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 16, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Symlin Generics:
There are no approved generic versions for Symlin as of now.
About Symlin
Symlin is a drug owned by Astrazeneca Ab. It is used for managing diabetes by regulating blood sugar levels and reducing post-prandial hyperglycemia. Symlin uses Pramlintide Acetate as an active ingredient. Symlin was launched by Astrazeneca Ab in 2007.
Approval Date:
Symlin was approved by FDA for market use on 25 September, 2007.
Active Ingredient:
Symlin uses Pramlintide Acetate as the active ingredient. Check out other Drugs and Companies using Pramlintide Acetate ingredient
Treatment:
Symlin is used for managing diabetes by regulating blood sugar levels and reducing post-prandial hyperglycemia.
Dosage:
Symlin is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) | INJECTABLE | Prescription | SUBCUTANEOUS |
| EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |
| EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) | INJECTABLE | Prescription | SUBCUTANEOUS |